Table of Contents: CATIE TreatmentUpdate

Table of Contents: CATIE TreatmentUpdate - 2002

Canadian AIDS Treatment Information Exchange
Edited by: Sean Hosein

Jump to Table of Contents

TreatmentUpdate 129: August - Vol. 14, No. 6

English

Françaises

THE XIV INTERNATIONAL AIDS CONFERENCE - Overview of conference
LA XIVe CONFÉRENCE INTERNATIONALE SUR LE SIDA : Survol de la conférence: HoseinSR; The recent International AIDS Conference, July 7-12, in Barcelona, was perhaps one of the more political of this series of conferences, if only because several current and former heads of state were among the more than 15,000 delegates. Many people in the world will be counting on these politicians, who include Bill Clinton and Nelson Mandela, to help in the effort to bring the worldwide spread of AIDS under control.
ANTI-HIV AGENTS : American-Italian study produces unexpected results
AGENTS ANTI-VIH : Une étude italo-américaine donne des résultats surprenants: HoseinSR; The availability of highly active antiretroviral therapy (HAART) since 1996 has helped to prolong survival for many people with HIV/AIDS (PHAs) in North America and countries of the European Union (EU). Yet HAART is not without limitations. For instance, although at least 15 anti-HIV drugs are licensed in Canada, none of them can cure HIV/AIDS. Moreover, caring for PHAs in the 21st century has become more complex than when HAART first appeared.
ANTI-HIV AGENTS : Tenofovir looks good in initial therapy
AGENTS ANTI VIH : Le ténofovir semble prometteur dans le cadre d'une combinaison d'attaque: HoseinSR; Tenofovir (Viread) is a relatively new anti-HIV drug that has been licensed in the United States and the countries of the European Union. In studies where tenofovir was used as part of combination therapy in heavily pre-treated HIV positive subjects, the drug helped lower viral loads and caused modest increases in CD4+ cell counts.
ANTI-HIV AGENTS : Tenofovir and Videx (ddI) EC — some caution required
AGENTS ANTI VIH : Le ténofovir et Videx EC — les chercheurs incitent à la prudence: HoseinSR; Since tenofovir (Viread) is a relatively new anti-HIV drug, not all interactions between it and the many other drugs used by people with HIV/AIDS (PHAs) are known. However, the manufacturer of tenofovir, Gilead Sciences, has recently reported an interaction with another anti-HIV drug — ddI (Videx EC, didanosine). Doctors may wish to alert their tenofovir- and ddI-using patients to this interaction.
ANTI-HIV AGENTS : T-20 shows its potency
AGENTS ANTI VIH : Le T-20 montre sa puissance: HoseinSR; Currently available anti-HIV therapy usually is able to suppress HIV activity, particularly in people with HIV/AIDS (PHAs) who are taking their first round of combination therapy. However, many PHAs will, at some point, develop treatment failure. As a result, new drugs are urgently needed.
From The XIV International AIDS Conference: Efavirenz makes its mark in AIDS
Des nouvelles en provenance de la XIVe Conférence internationale sur le sida : L'efavirenz laisse sa marque sur le sida: HoseinSR; People who have the life-threatening infections that are the hallmark of AIDS are often excluded from the initial round of clinical trials of AIDS drugs. Therefore, the effectiveness of some anti-HIV drugs in this population may not be well documented. To try to assess the impact of efavirenz (Sustiva, Stocrin) on AIDS, researchers in Barcelona, Spain, reviewed the hospital records of 92 subjects who had symptoms of AIDS and who used this drug.
TESTING : Study finds fatigue linked to quality of sleep
TESTS : Une étude révèle que la fatigue est reliée à la qualité du sommeil: HoseinSR; Fatigue has long been associated with HIV/AIDS. In some people with HIV/AIDS (PHAs), fatigue can be so severe that it is disabling.
TESTING : High liver enzyme levels — a warning about survival?
TESTS : L'élévation des taux d'enzymes hépatiques – une menace pour la survie?: HoseinSR; Lab tests can detect levels of certain proteins commonly called liver enzymes.
NUTRITION : Nutrient deficits found in some HIV positive people
NUTRITION : Des carences nutritionnelles sont décelées chez certaines personnes séropositives: HoseinSR; Deficits of nutrients have been linked to a declining immune system and reduced survival among some HIV positive people. There may be many factors that lead to the development of nutrient deficits.
NUTRITION : Low zinc intake linked to reduced survival
NUTRITION : Un faible apport en zinc est lié à une réduction de la survie: HoseinSR; Nutrients play an important role in maintaining the health of the immune system. In a study related to the previously mentioned one, researchers Marianna Baum and Adriana Campa have been studying the the relation between nutrient deficits and immunity for many years.

TreatmentUpdate 132: December - Vol. 14, No. 9: INTRODUCTION: What's a conference about ?; SIDE EFFECTS: Who gets treatment and... side effects; SIDE EFFECTS: Protection from nuke side effects; SIDE EFFECTS: Breaking free from nukes; ADHERENCE: What helps adherence to therapy?; VACCINES: Rub-on vaccine study planned; CANCER: Cancer risk falls in some HAART users; INFECTIONS: Syphilis - the great masquerader; INFECTIONS: Is hepatitis C virus going to become a major STD
TreatmentUpdate 131: November - Vol. 14, No. 8: SIDE EFFECTS: The usual suspects; SIDE EFFECTS: A brief history of HIV drug therapy; SIDE EFFECTS: Strange side effects; SIDE EFFECTS: Focus on fat; SIDE EFFECTS: Lots of volunteers needed; SIDE EFFECTS: Lactic acid and nuke damage; SIDE EFFECTS: No nukes please; SIDE EFFECTS: Fat wasting - AZT vs. d4T; SIDE EFFECTS: Sugar blues; SIDE EFFECTS: Predicting body shape changes; SIDE EFFECTS: Niacin for high triglycerides; SIDE EFFECTS: Supplement fix for nelfinavir-related diarrhea
TreatmentUpdate 130: September/October - Vol. 14, No. 7: ANTI-HIV AGENTS - Drug holidays - an overview ; ANTI-HIV AGENTS - Here's a story about a drug holiday ; TOXICITY - Milk thistle and indinavir ; TESTING - Some factors affecting survival in HIV positive women ; ANTI-CANCER AGENTS - A new treatment for Kaposi's sarcoma
TreatmentUpdate 129: August - Vol. 14, No. 6: THE XIV INTERNATIONAL AIDS CONFERENCE - Overview of conferencel; ANTI-HIV AGENTS : American-Italian study produces unexpected results; ANTI-HIV AGENTS : Tenofovir looks good in initial therapy; ANTI-HIV AGENTS : Tenofovir and Videx (ddI) EC — some caution required; ANTI-HIV AGENTS : T-20 shows its potency; ANTI-HIV AGENTS : Efavirenz makes its mark in AIDS; TESTING : Study finds fatigue linked to quality of sleep; TESTING : High liver enzyme levels — a warning about survival?; NUTRITION : Nutrient deficits found in some HIV positive people; NUTRITION : Low zinc intake linked to reduced survival
TreatmentUpdate 128: July - Vol. 14, No. 5: SIDE EFFECTS: Sexual dysfunction in men: A report from France; SIDE EFFECTS: Sexual dysfunction in men: A report from Boston; SIDE EFFECTS: Male sexual dysfunction and HAART — the confusion continues; SIDE EFFECTS: Study finds problems with reporting side effects; ANTI-CANCER AGENTS: Recurring cervical growths; ANTI-HIV AGENTS: Starting therapy: study finds guidelines linked to level of immunity
TreatmentUpdate 127: May/June - Vol. 14, No. 4: ANTI-HIV AGENTS: Delavirdine in rescue regimens; ANTI-HIV AGENTS: Could cimetidine be used as a booster?; ANTI-HIV AGENTS: Teaching adherence to substance users; Fine-tuning saquinavir; ANTI-HIV AGENTS: Invirase vs. Fortovase: unexpected results?; ANTI-HIV AGENTS: Saquinavir once daily; ANTI-HIV AGENTS: Saquinavir with low-dose ritonavir twice daily; ANTI-HIV AGENTS: Highlights from the 3rd International Workshop on Clinical Pharmacology of HIV Therapy
TreatmentUpdate 126: March - Vol. 14, No. 3: SIDE EFFECTS : Protease inhibitors and lipid-lowering drugs -- interactions; Cause of serious illness among HAART-users not clear; Using abacavir to avoid lipid problems; Switching to abacavir to reduce fat wasting; 9th Retrovirus Overview; SIDE EFFECTS : Assessing nuke toxicity; SIDE EFFECTS : Check-ups for the power plant?; SIDE EFFECTS : Damage to the power plant
TreatmentUpdate 125: February - Vol. 14, No. 2: SIDE EFFECTS: Comparing liver toxicity between efavirenz and nevirapine; SIDE EFFECTS: Nevirapine levels may predict toxicity; SIDE EFFECTS: Health Canada advises against kava; SIDE EFFECTS: Birth defect in baby born to efavirenz-user; SIDE EFFECTS: Viagra and grapefruit juice - not a good mix; INFECTION FIGHTERS: Cidofovir and surgery for genital warts; ANTI-HIV AGENTS: Swiss study switching to efavirenz
TreatmentUpdate 124: January - Vol. 14, No. 1: SIDE EFFECTS: Testosterone troubles; SIDE EFFECTS: Growth hormone: Does less equal more?; SIDE EFFECTS: Thyroid troubles in Montreal; SIDE EFFECTS: Thyroid troubles in France; HIGHLIGHTS FROM ICAAC: Directly observed therapy (DOT); HIGHLIGHTS FROM ICAAC: Amprenavir and low-dose ritonavir; HIGHLIGHTS FROM ICAAC: Saquinavir vs. Sustiva once daily; HIGHLIGHTS FROM ICAAC: Tenofovir; HIGHLIGHTS FROM ICAAC: Atazanavir boosts saquinavir; HIGHLIGHTS FROM ICAAC: Atazanavir vs. nelfinavir; HIGHLIGHTS FROM ICAAC: Atazanavir overview; ANTI-HIV AGENTS: Starting HAART and its effect on survival; ANTI-HIV AGENTS: Response to HAART depends on T-cell count; ANTI-HIV AGENTS: Delaying therapy - the pendulum swings back
Copyright / Staff / How to Contact

ÆGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1990,2002. ÆGiS . All materials appearing on ÆGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of ÆGIS , or the party credited as the provider of the content. Please contact the party credited as the provider of the content for permission to reproduce.

TreatmentUpdate 129: August - Vol. 14, No. 6

Table Of Contents